학술논문
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Document Type
Article
Author
Logunov, D.Y.; Dolzhikova, I.V.; Zubkova, O.V.; Tukhvatullin, A.I.; Shcheblyakov, D.V.; Dzharullaeva, A.S.; Grousova, D.M.; Erokhova, A.S.; Kovyrshina, A.V.; Botikov, A.G.; Izhaeva, F.M.; Popova, O.; Ozharovskaya, T.A.; Esmagambetov, I.B.; Favorskaya, I.A.; Zrelkin, D.I.; Voronina, D.V.; Shcherbinin, D.N.; Semikhin, A.S.; Simakova, Y.V.; Tokarskaya, E.A.; Lubenets, N.L.; Egorova, D.A.; Shmarov, M.M.; Nikitenko, N.A.; Naroditsky, B.S.; Gintsburg, A.L.; Morozova, L.F.; Smolyarchuk, E.A.; Kryukov, E.V.; Babira, V.F.; Borisevich, S.V.
Source
In: The Lancet . (The Lancet, 26 September - 2 October 2020, 396(10255):887-897)
Subject
Language
English
ISSN
1474547X
01406736
01406736